This time for the first time India Incorporation Biopharmaceutical Company was present in JP Morgan Health conference......Biocon was represented by Kiran Shaw Majumdar...listed below are facts about Biocon.
Biocon being major player in statins, immunosuppressant’s and global scale Mab production
Being in number one position for Insulin production in Asia
Its services for drug discovery (Syngene) to clinical trials (Clingene) for word class pharmaceutical companies, start ups
Its two major drugs which are in Phase III clinical development
Oral Insulin tablet -IN105- It has started its Six month double control placebo studies- for Type II diabetes which it is planning to launch in emerging market.
Tih Anti-CD6 Antibody which has entered into Phase III clinical studies for Psoriasis and it is going to start phase III studies for Rheumatoid arthritis.
Biocon has recently filed one more IND of the same compound in December 2009 as from preclinical studies it has got some evidence that the said Anti-CD6 antibody can be used for some metabolic disorder treatment.Biocon seeking more alliances in Monoclonal antibody discovery and production.
Note: Biocon is $1.2 Billion India based enzyme and Biopharma Company with more than 1000 patents filed and 200 granted patents which became public in year 2004.
No comments:
Post a Comment